RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.
RayzeBio has raised $160.0M in total funding. The most recent round was Series D. The last funding was announced in September 2022.
RayzeBio's investors include Cormorant Asset Management, Vivo Capital, Sands Capital Ventures, TCG Crossover, Wellington Management.
RayzeBio is headquartered in San Diego, United States.
RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.
RayzeBio is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"RayzeBio — Funding & Investors." VCBacked, September 13, 2022, https://www.vcbacked.co/company/rayzebio. Accessed July 19, 2026.
VCBacked. (2022). RayzeBio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/rayzebio
{{cite web |title=RayzeBio — Funding & Investors |url=https://www.vcbacked.co/company/rayzebio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated